The Compounder's Trap

There is a dangerous idea circulating among long-term investors. It sounds wise. It sounds patient. It sounds like something Warren Buffett would say. The idea is this: if a company is truly great, you should never sell it. Hold forever. Let the compounding do its work. Sit on your hands.

It is a seductive idea. And, like most seductive ideas, it contains just enough truth to be genuinely dangerous.

The past two decades have been extraordinarily kind to the quality-growth investing style. Investors who identified exceptional compounders early — businesses with durable competitive advantages, high returns on capital, and management teams that reinvest wisely — were richly rewarded. The names are familiar: LVMH, Hermès, Constellation Software, Danaher, Rational AG. Companies that seemed "expensive" at 25x earnings turned out to be cheap, because their earnings kept growing at 15–20% a year for decade after decade.

This track record created a school of thought. Influenced by investors like Terry Smith, Nick Sleep, and François Rochon, a generation of quality-focused practitioners came to believe that valuation matters far less than business quality. "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price," as the famous aphorism goes. The logic is mathematically sound: a business compounding intrinsic value at 15% per year will eventually justify almost any starting valuation, given enough time.

But here is the part that often gets quietly omitted from this story: given enough time is doing a lot of heavy lifting in that sentence.

Let's be precise about what "valuation doesn't matter for great businesses" actually means. It doesn't mean that paying 80x earnings for a wonderful company is the same as paying 25x. It means that, over a sufficiently long horizon, the difference in returns between those two entry points will diminish — provided the business keeps compounding intrinsic value.

The problem is that real investors don't have infinite time horizons. They have portfolios to manage, life events that require liquidity, and psychological tolerance for drawdowns that is always more limited in practice than it seems in theory. And compounders, even genuine ones, can go through very long periods of painful de-rating when starting valuations are too extreme.

Consider Nestlé. For decades, it was considered one of the safest, most reliable compounders on the Swiss exchange. A collection of dominant brands, global distribution, pricing power, steady cash generation. In 2021, investors were paying roughly 27–28x earnings for this privilege — not absurd, but clearly pricing in continued flawless execution. What followed was a sobering reminder that high multiples leave no room for operational hiccups — and Nestlé delivered several. Organic growth deteriorated until real internal growth turned negative. Retailers pushed back aggressively on pricing. The GLP-1 drug narrative cast a shadow over the food sector. IT integration stumbled. CEO Mark Schneider was eventually ousted. The business had not become worthless — but at 28x earnings, investors were paying for perfection. Perfection is rarely permanent. By 2024, the stock had lost roughly 30% in total return terms over three years. The lesson is not that Nestlé is a bad business. It remains a formidable franchise — but a demanding multiple turns every operational imperfection into a valuation catastrophe.

Understanding why compounders de-rate is essential to navigating the trap. There are typically three triggers.

The first is mean reversion in growth expectations. Markets are forward-looking. When a quality compounder is trading at 40x earnings, the implicit assumption baked into that price is not just that the business is good — it's that it will remain exceptional, that returns on capital will stay elevated, that reinvestment opportunities will continue. When growth inevitably slows — as it does for every business eventually, even the greatest ones — the multiple collapses. The business earns 10% more; the stock falls 20%. The arithmetic of de-rating is brutal.

The second is the rate sensitivity of long-duration assets. A business with most of its value in cash flows 10–20 years from now behaves like a long-dated bond. When risk-free rates rise, the discount rate used to value those future cash flows rises, and present values fall. This is precisely what happened to many high-multiple quality businesses in 2022–2023, when rate normalisation after a decade of near-zero interest rates caused violent re-ratings across the quality spectrum. Companies whose businesses were fundamentally unchanged fell 40–50% — not because anything was wrong operationally, but because the valuation cushion was insufficient.

The third is the narrative shift. Quality investing is, partly, a narrative game. A compounder trading at a premium multiple benefits from a self-reinforcing story: analysts write positively, institutional investors benchmark-hug into the position, retail investors follow. When that narrative cracks — a missed earnings quarter, a CEO departure, a competitive threat — the reversal can be swift and disproportionate. The same investors who overpaid on the way up capitulate on the way down.

So how do you know when the price has run too far ahead of reality? One of the most useful tools available is the Reverse DCF. Instead of predicting the future to arrive at a fair value, you take the current stock price and solve backwards. What growth rate, sustained for how many years, at what margins, must the business deliver to justify what you are being asked to pay today? If the answer reveals that your favourite European mid-cap needs to capture 150% of its Total Addressable Market over the next decade just to justify today's multiple, the narrative has quietly decoupled from reality. The Reverse DCF does not tell you when the market will notice — but it tells you, with cold arithmetic, what you are implicitly betting on. Sometimes that number is reasonable. Often, for a beloved compounder at peak sentiment, it is not.

Which brings us to Germany, and a chance to apply the Reverse DCF in practice.

Rational AG is one of Europe's finest industrial businesses. The German manufacturer of professional combi-ovens holds an almost unassailable position in professional kitchens worldwide, with gross margins exceeding 60% and returns on equity that would make most businesses weep with envy. It is, by any quality-investing framework, a genuine compounder.

And yet, investors who bought Rational in early 2021 — at roughly 60x earnings — were making a very specific implicit bet. It is worth noting that part of the 2020–2021 P/E spike was mechanical: COVID had shuttered professional kitchens worldwide, temporarily crushing near-term earnings and inflating the multiple arithmetically. But as hospitality recovered and earnings normalised through 2021, the multiple remained stubbornly elevated — suggesting that sentiment, not just a distorted denominator, was doing the heavy lifting. Even stripping out the COVID noise, a Reverse DCF at 2021 prices implied that Rational needed to grow its free cash flow at approximately 18–20% annually, sustained for a full decade, to justify the multiple at a reasonable discount rate. For a mature, hardware-based industrial company selling combi-ovens to professional kitchens — even the undisputed global leader in its niche — that is a demanding mathematical assumption. Not impossible. But a fairy tale if treated as a base case.

Over the eighteen months that followed, the stock fell nearly 40% — not because the business broke, but because the price had nowhere to go but down. The business itself was largely unaffected. It continued to generate excellent returns on capital and remained the dominant player in its niche. But the entry price had been so demanding that even this exceptional business could not grow its way out of the valuation in the short-to-medium term.

The lesson is not "don't buy Rational." The lesson is: the price you pay determines how much of the company's future success you get to keep.

Terry Smith famously says: "Don't just do something, sit there." It is excellent advice — for most situations. The risk of over-trading in quality portfolios is real and well-documented. Transaction costs, capital gains tax, and the behavioural tendency to sell winners too early and hold losers too long mean that activity is usually the enemy of returns.

But "hold forever" was never meant to mean "hold regardless of price." Even Nick Sleep and Qais Zakaria, the managers of the Nomad Investment Partnership and perhaps the purest expression of the long-duration quality investing philosophy, were price-sensitive in their purchases. They were willing to hold because they had bought at prices that gave them margin of safety. The holding discipline was downstream of valuation discipline at the point of purchase.

The "hold forever" maxim has been distorted in popular investing culture into an excuse not to think about price at all. This is a misreading. What it really means is: once you own a genuinely superior business at a reasonable price, your default posture should be patience. It does not mean that a business priced for perfection should be held through all cycles without scrutiny.

If we accept that even quality compounders can become dangerously overvalued, what should a thoughtful investor do? Selling entirely is usually wrong — transaction costs, taxes, and the difficulty of reinvesting proceeds at equivalent quality create a high bar. But the alternative is not paralysis.

Before reaching for any framework, the honest investor must confront one uncomfortable mathematical reality: the tax hurdle. For a position bought a decade ago and sitting on a 500% unrealised gain, selling triggers an immediate and guaranteed destruction of 20–30% of that gain — depending on jurisdiction — before a single euro of proceeds can be redeployed. To justify selling, you must believe the anticipated de-rating will be worse than the certain, immediate tax penalty you are paying to exit. This is the strongest genuine argument for the "hold forever" camp, and it deserves respect. It does not make selling wrong — but it does raise the bar considerably. A modest multiple expansion, or a business trading at 30x when fair value might be 25x, rarely clears that hurdle. A business trading at 60x earnings on aggressive assumptions might. The tax hurdle does not resolve the question; it sharpens it.

A useful framework has three components.

1. Track intrinsic value, not just price. Every quarter, ask: has the business's intrinsic value grown in line with or faster than its price? If the stock has appreciated 40% over two years while earnings and free cash flow have grown 10%, the valuation gap has widened. That gap is a risk, not a reward.

2. Set prospective return thresholds. For a quality compounder, a reasonable long-term expectation might be an 8–10% annualised return. At a given price, what earnings growth rate and exit multiple must materialise for that to happen? If the answer requires sustained 20% earnings growth for a decade and a multiple that never contracts, you are relying on a scenario, not an expectation.

3. Consider asymmetric trimming. If a compounder has grown from a 4% portfolio position to 12% purely through price appreciation, rebalancing back towards 6–8% is not a philosophical betrayal of quality investing — it is prudent risk management. You retain meaningful exposure to continued upside while reducing the impact of a de-rating event.

The irony of the "hold forever" culture is that Warren Buffett himself, its supposed patron saint, has never been dogmatic about it. Berkshire Hathaway trimmed its Apple position materially in 2024 — driven by portfolio concentration concerns, explicit tax considerations (Buffett noted at the 2024 Annual Meeting that he anticipated higher corporate tax rates ahead, making it prudent to lock in gains at current rates), and because he judged the valuation offered less prospective return than the alternatives, including simply holding cash.

"I never attempt to make money on the stock market," Buffett has said. "I buy on the assumption that they could close the market the next day and not reopen it for five years." But notably, he also said: "Price is what you pay, value is what you get." These two ideas must be held together. The patience to hold through volatility is only rational if the price paid in the first place embedded sufficient value.

There is a final dimension to the compounder's trap that rarely gets discussed: the opportunity cost of overpaying. Capital locked into a priced-for-perfection compounder at 50x earnings is capital not available for the next Rational AG at 20x, or the unloved Japanese industrial trading at a discount to its net cash, or the European mid-cap with a dominant niche that the market hasn't yet noticed.

Quality investing is not just about finding great businesses. It is about finding great businesses at prices that allow those businesses to reward you. The identification skill and the valuation discipline are inseparable. Strip out the valuation discipline, and quality investing becomes a momentum strategy dressed in long-term clothing.

The compounders you hold in your portfolio should earn their place not just through the quality of their businesses, but through the reasonableness of what you paid for them. When a position's prospective return has fallen below your hurdle rate — not because the business deteriorated, but purely because the price has run — that is not a reason to congratulate yourself. It is a reason to think carefully.

The greatest compounders in history rewarded their long-term shareholders not only because they were exceptional businesses, but because those shareholders bought them at prices that respected the uncertainty of the future. Hermès at 15x earnings in 2010 was a different bet from Hermès at 55x earnings in 2023 — even though the business was the same extraordinary franchise.

Quality investing, done well, is the combination of a scout's eye for business excellence and an accountant's discipline about price. The first skill gets the headlines. The second skill, quietly and consistently applied, is what separates the investors who compound wealth from those who merely collect expensive stories about companies they admire.

Don't confuse the two.

YAIN — Yet Another Investing Newsletter
The views expressed are for educational purposes only and do not constitute investment advice.